1. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
    Cell Cycle/DNA Damage
  2. EGFR
  3. CUDC-101


製品番号: HY-10223 純度: 99.02%

CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4, 2.4, and 15.7 nM, respectively.


CUDC-101 構造式

CUDC-101 構造式

CAS 番号 : 1012054-59-9

容量 価格(税別) 在庫状況 数量
無料サンプル (0.5-1 mg)   今すぐ申し込む  
10 mM * 1 mL in DMSO USD 55 在庫あり
Estimated Time of Arrival: December 31
5 mg USD 50 在庫あり
Estimated Time of Arrival: December 31
10 mg USD 90 在庫あり
Estimated Time of Arrival: December 31
25 mg USD 150 在庫あり
Estimated Time of Arrival: December 31
50 mg USD 250 在庫あり
Estimated Time of Arrival: December 31
100 mg USD 450 在庫あり
Estimated Time of Arrival: December 31
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください


Based on 8 publication(s) in Google Scholar

Top Publications Citing Use of Products

    CUDC-101 purchased from MCE. Usage Cited in: Am J Cancer Res. 2018 Dec 1;8(12):2402-2418

    Western analysis of protein levels of p-p53, cl-caspase3 and the ratio of bax/bcl-2 in the treatment of Germ or/and CUDC.

    CUDC-101 purchased from MCE. Usage Cited in: Am J Cancer Res. 2018 Dec 1;8(12):2402-2418

    PANC-1 and MIA PaCa-2 cells are treated with CUDC-101 and/or gemcitabine for 48 h, and western blot analysis shows increased inhibition of the PI3K, p-Akt, p-S6, p-4EBP1 and p-Erk proteins.
    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー


    CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4, 2.4, and 15.7 nM, respectively.

    IC50 & Target[1]


    2.4 nM (IC50)


    15.7 nM (IC50)


    4.4 nM (IC50)


    4.5 nM (IC50)


    12.6 nM (IC50)


    9.1 nM (IC50)


    13.2 nM (IC50)


    5.1 nM (IC50)


    11.4 nM (IC50)


    67.2 nM (IC50)


    26.1 nM (IC50)


    79.8 nM (IC50)


    373 nM (IC50)


    CUDC-101 inhibits both class I and class II HDACs, but not class III, Sir-type HDACs. CUDC-101 displays broad antiproliferative activity in many human cancer cell types. CUDC-101 is a potent and selective HDAC, EGFR, and HER2 inhibitor with only weak inhibition of the following protein kinases (IC50): KDR (VEGFR2) (849 nM), Src (11000 nM), Lyn (840 nM), Lck (5910 nM), Abl-1 (2890 nM), FGFR-2 (3430 nM), Flt-3 (1500 nM), and Ret (3200 nM)[1]. CUDC-101 (300 nM) inhibits both the full length AR (flAR) and the AR variant AR-V7[2]. CUDC-101 is the most active agent in all three ATC cell lines screened for inhibitors of EGFR and HDACs, with half-maximal inhibitory concentration (IC50) at 0.15 μM for 8505c, and 1.66 μM for both C-643 and SW-1736 cells. CUDC-101 inhibits cancer cell migration and modulates epithelial-mesenchymal transition marker expression in ATC cells. CUDC-101 also inhibits HDAC and MAPK pathway, induces p21, and decreases survivin and XIAP expression in ATC cells[3]. CUDC-101 (1 μM) increases the acetylation of p53 and α-tubulin, nonhistone substrates of HDAC, in treated cancer cells. CUDC-101 modulates RTK activity and expression and exhibits immediate and stable inhibition of RTK and downstream Akt signaling[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.


    CUDC-101 (120 mg/kg, iv, daily) induces tumor regression in the Hep-G2 liver cancer model and is more efficacious than erlotinib at its maximum tolerated dose (MTD). In the erlotinib-resistant A549 NSCLC xenograft model, CUDC-101 (120 mg/kg) shows potent inhibition of tumor growth. In the erlotinib-sensitive H358 NSCLC models, CUDC-101 (15, 30, 60 mg/kg, i.v.) inhibits tumor growth in a dose-dependent manner. CUDC-101 (120 mg/kg) causes significant tumor regression in the lapatinib-resistant, HER2-negative, EGFR-overexpressing MDA-MB-468 breast cancer model and the EGFR-overexpressing CAL-27 head and neck squamous cell carcinoma (HNSCC) model. CUDC-101 (120 mg/kg) also inhibits tumor growth in the K-ras mutant HCT116 colorectal and EGFR/HER2 (neu)-expressing HPAC pancreatic cancer models[1]. In an in vivo mouse model of metastatic ATC, CUDC-101 inhibits tumor growth and metastases, and significantly prolongs survival[3]. CUDC-101 (120 mg/kg) is effective against a broad range of tumor types in xenograft models[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.





    CAS 番号





    Room temperature in continental US; may vary elsewhere.

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度

    DMSO : 25 mg/mL (57.54 mM; Need ultrasonic)

    H2O : < 0.1 mg/mL (insoluble)

    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3015 mL 11.5077 mL 23.0155 mL
    5 mM 0.4603 mL 2.3015 mL 4.6031 mL
    10 mM 0.2302 mL 1.1508 mL 2.3015 mL
    *Please refer to the solubility information to select the appropriate solvent.
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (5.75 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: 2.5 mg/mL (5.75 mM); Suspended solution; Need ultrasonic

    *All of the co-solvents are provided by MCE.

    The activities of Class I and II HDACs are assessed using the Biomol Color de Lys system. Briefly, HeLa cell nuclear extracts are used as a source of HDACs. Different concentrations of drugs are added to HeLa cell nuclear extracts in the presence of a colorimetric artificial substrate. Developer is added at the end of the assay and enzyme activity is measured in the Wallac Victor II 1420 microplate reader at 405 nM.

    MCE はこれらの方法の精度を確認していません。 こちらは参照専用です。


    Cancer cell lines are plated at 5000 to 10 000 cells per well in 96-well flat-bottomed plates with varying concentrations of compounds. The cells are incubated with compounds for 72 h in the presence of 0.5% of fetal bovine serum. Growth inhibition is assessed by an adenosine triphosphate (ATP) content assay using the Perkin-Elmer ATPlite kit.

    MCE はこれらの方法の精度を確認していません。 こちらは参照専用です。


    Four- to six-week-old female athymic mice (nude nu/nu CD-1) are inoculated subcutaneously into the right hind flank region with 1 to 5×106 cells in a medium suspension of 100−200 μL. For orthotopic implantation of breast cancer cells, a cell suspension in 100 μL of medium is injected directly into the mammary fat pads through a 27G needle. Different doses of CUDC-101, standard anticancer agents and vehicle are administered orally, intraperitoneally, or via tail vein injection as indicated.

    MCE はこれらの方法の精度を確認していません。 こちらは参照専用です。


    純度: 99.02%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • モル濃度カルキュレーター

    • 希釈カルキュレーター

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2


    CUDC-101CUDC101CUDC 101EGFRHDACEpidermal growth factor receptorErbB-1HER1Histone deacetylasesInhibitorinhibitorinhibit



    Your information is safe with us. * Required Fields.




    お名前 *


    PC 用メールアドレス *

    電話番号 *


    勤務先/学校名 *

    Department *


    カスタマ需要量 *

    国会或いは地域 *





    Inquiry Information

    MCE 日本正規代理店: